Multiple sclerosis and related disorders · 2025
"Effectiveness and associated factors of response to Fampridine in multiple sclerosis: A prospective observational study from an expert center".
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Martinez-Campos Elisa, Robles Miguel Angel, Horno Rosalia, Meza Roger, Sánchez Samuel, Castilló Joaquín, Vidal-Jordana Angela, Zabalza Ana, Rodríguez-Acevedo Breogán, Vilaseca Andreu, Arrambide Georgina, Pappolla Agustín, Midaglia Luciana, Galán Ingrid, Ariño Helena, Carvajal René, Mongay Neus, Cobo-Calvo Álvaro, Comabella Manuel, Tur Carmen, Sastre-Garriga Jaume, Tintoré Mar, Montalban Xavier, Río Jordi
Аннотация
OBJECTIVE: To evaluate the effectiveness of fampridine on gait performance in patients with multiple sclerosis (MS) and to identify clinical predictors of therapeutic response.
METHODS: Prospective observational study of 197 MS consecutive patients with walking impairment (EDSS 4.0-7.00) treated with fampridine between 2018 and 2024. Gait was assessed using the Timed 25-Foot Walk (T25FW), 2-Minute Walk Test (2MWT), and the 12-item Multiple Sclerosis Walking Scale (MSWS-12) at five timepoints over a 12-month follow-up. Responders were defined as those with ≥20 % improvement in T25FW or ≥6-point reduction in MSWS-12. A multivariable logistic regression was performed to identify independent predictors of response.
RESULTS: Significant improvements were observed across all gait measures (p < 0.001) in the follow-up visits. Male sex (OR=2.375; p = 0.018) and higher baseline MSWS-12 scores (OR=1.141; p = 0.001) were associated with increased likelihood of response. Older age (OR=0.962; p = 0.028) and higher baseline EDSS (OR=0.356; p < 0.001) were associated with reduced probability of response. Fampridine was well tolerated, with a 33 % discontinuation rate at the end of follow-up, mainly due to perceived lack of benefit.
CONCLUSION: Fampridine significantly improves gait performance in MS patients in real-world settings. Simple clinical variables such as age, sex, EDSS, and subjective walking impairment (MSWS-12) may help identify individuals most likely to benefit from treatment.
METHODS: Prospective observational study of 197 MS consecutive patients with walking impairment (EDSS 4.0-7.00) treated with fampridine between 2018 and 2024. Gait was assessed using the Timed 25-Foot Walk (T25FW), 2-Minute Walk Test (2MWT), and the 12-item Multiple Sclerosis Walking Scale (MSWS-12) at five timepoints over a 12-month follow-up. Responders were defined as those with ≥20 % improvement in T25FW or ≥6-point reduction in MSWS-12. A multivariable logistic regression was performed to identify independent predictors of response.
RESULTS: Significant improvements were observed across all gait measures (p < 0.001) in the follow-up visits. Male sex (OR=2.375; p = 0.018) and higher baseline MSWS-12 scores (OR=1.141; p = 0.001) were associated with increased likelihood of response. Older age (OR=0.962; p = 0.028) and higher baseline EDSS (OR=0.356; p < 0.001) were associated with reduced probability of response. Fampridine was well tolerated, with a 33 % discontinuation rate at the end of follow-up, mainly due to perceived lack of benefit.
CONCLUSION: Fampridine significantly improves gait performance in MS patients in real-world settings. Simple clinical variables such as age, sex, EDSS, and subjective walking impairment (MSWS-12) may help identify individuals most likely to benefit from treatment.